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variable dependent on PTH levels. Thus, it seems statis-
tically inappropriate to apply this factor as independent
variables in the stepwise regression assay to detect “the
patients with high plasma intact PTH levels.”
Taken together, we regret to conclude that we could not
perform the stepwise analyses including active vitamin D
treatment as an independent variable in this study. We
hope your attractive hypothesis will be proved in some
other opportunities.
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Combination of intravenous
iron sucrose and ascorbic acid
in hemodialysis patients
To the Editor: We read with great interest the recent
article by Sturm et al [1] demonstrating ascorbic acid
together with iron sucrose can increase the intracellu-
lar labile iron pool and iron mobilization to transferrin
in human hepatoma HepG2 cells. The authors reported
that neither ferric gluconate nor iron dextran has such
an effect. The extrapolation of this important finding to
clinical practice, as it was noted in the manuscript, led to
the conclusion that iron sucrose could be a more benefi-
cial iron preparation for further response to recombinant
human erythropoietin (rHuEPO) with adjuvant ascorbic
acid replacement. As it was cited in the paper, the studies
investigating the role of ascorbic acid as an adjuvant ther-
apy to rHuEPO enrolled the hemodialysis patients with
iron overload. Most of the studies on this issue excluded
the patients on iron replacement due to iron overload [2,
3] and reported a beneficial effect of ascorbic acid only
in patients with functional iron deficiency. The effect of
concomitant use of ascorbic acid with intravenous iron on
rHuEPO response has not been extensively evaluated.
However, in our recent randomized crossover study, we
investigated this issue in all hemodialysis patients, includ-
ing patients with normal iron status, as well. All patients
were on maintenance intravenous iron sucrose and were
administrated 500 mg ascorbic acid 3 times a week for 6
months. We found that supplementation of ascorbic acid
resulted in a significant increase in hemoglobin levels to-
gether with a significant increase in transferrin saturation
in approximately 65% of the patients [4]. Therefore, iron
sucrose and ascorbic acid can be a better combination
due to increasing the amount of bioavailable iron from
iron sucrose. However, we recommend further clinical
studies to evaluate the effect of other intravenous iron
preparations in combination with ascorbic acid.
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Continuous renal replacement
therapy in the critically ill
patient
To the Editor: I read with interest the discussion of
Dr. Mehta [1]. As “positive” findings, I see the follow-
ing: (1) The treatment protocol is adapted to the widely
available Prisma machine. Nevertheless, in the future I
hope to see more versatile models permitting the use of
other than Hospal filters, Hospal “sets,” and more flexible
pump functions; (2) the recipe for citrate local anticoagu-
lation, which reduces side effects in patients und prolongs
filter function; (3) the great idea of partial predilution
